An interventional study of communication in Tobacco Products, Cigarettes and Electronic Cigarettes, sponsored by UNC Lineberger Comprehensive Cancer Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by UNC Lineberger Comprehensive Cancer Center · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 287 studies in Vaping with a site in United States — 65 open to participants now, 73 under way, 1 of them phase 3. Vaping · United States.
Among the 287 studies in Vaping with a site in United States, this one is the 111th largest by enrollment of the 257 interventional ones that give a count, is one of 21 that started in 2026, is one of 205 with no phase, and was the 274th registered.
403 studies on the registry are indexed under Vaping; 96 are open to participants now.
Browse Vaping studies →65 of the 287 studies in Vaping with a site in United States are open now. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 21+ · Healthy volunteers
Yale University · Sites in United States
Ages 21–44 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18–65
University of Nebraska · Sites in United States
Ages 15–18
Prisma Health-Upstate · Sites in United States
Ages 21+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 64 Vaping studies recruiting now, 32 (50%) set no upper age limit and 31 (48%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
287 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 21 · Phase 3 4 · Phase 4 12
First in 2013; this study’s year is marked. 21 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 99 is above the median of 80 across 323 interventional studies indexed under Vaping.
Median enrollment 71 across the 257 interventional studies, 110 across the 30 observational. Of the 202 that completed or were terminated, 87 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 287 have an industry lead sponsor. The 10 most frequent:
UNC Lineberger Comprehensive Cancer Center is the lead sponsor of 429 studies on the registry; 97 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
UNC Lineberger Comprehensive Cancer Center has 5 studies filed under Vaping — fewer than ten, so there is no comparison to draw.
30 of the studies in Vaping with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07322432VapeAwayThe CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction | 2026-12 |
| NCT06159608Anna Stanhewicz, PhDSex Differences in the Vascular Effects of E-cigarette Use | 2026-12 |
| NCT04661683University of California, Los AngelesSecondhand Effects of Hookah (i.e., Waterpipe) Smoke and Aerosol | 2026-12-15 |
| NCT07553585Yale UniversitySurvey to Test the Nicotine Concentration and Nicotine Flux Labels for E-cigarettes | 2026-12-15 |
| NCT04907136Florida International UniversityDeveloping and Testing Health Warning Labels on the ENDS Device | 2026-12-30 |
Add all 30 to your calendar (.ics) → With an account.
Among the 287 studies in Vaping with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is a pilot test of effectiveness of communication campaign ads on interest in quitting combustible cigarettes and e-cigarettes. Over the course of 5 weeks, participants are sent ads that are designed to encourage quitting and then answer surveys.
Qualtrics Services will enroll 90 US adult dual users to participate in this study using existing panels. Inclusion criteria are current cigarette and e-cigarette use, age 18 or older, and ability read and answer questions in English, and willingness to receive text messages. Qualtrics will contact, screen, consent and randomize participants into 1 of 2 study arms: exposure to a 3 cycles of 6 ads encouraging them to quit smoking and vaping simultaneously or 6 ads encouraging them to quit sequentially (quitting smoking first followed by quitting vaping). The ads (one per day) are presented along with brief daily surveys. The primary outcome in intent to quit smoking.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in this arm receive messages encouraging them to quit both cigarettes and e-cigarettes at the same time.
Other: communication
Participants in this arm receive messages encouraging them to quit cigarettes first, followed by e-cigarettes.
Other: communication
Participants view an image that is an ad designed to encourage them to quit their use of cigarettes and e-cigarettes.
Also known as: advertising
Cigarette quit intention
A three question scale of interest in quitting cigarettes: How \[interested are you in quitting / likely are you to quit / much do you intend to quit\] smoking cigarettes in the next 6 months? 4 point response scale.
Time frame: Measured at baseline (Day 0) weekly surveys (Days 7, 14), post 1 survey (Day 21), and post 2 survey (Day 35)
E-cigarette quit intention
A three question scale of interest in quitting vaping (e-cigarettes): How \[interested are you in quitting / likely are you to quit / much do you intend to quit\] vaping in the next 6 months? 4 point response scale.
Time frame: Measured at baseline (Day 0) weekly surveys (Days 7, 14), post 1 survey (Day 21), and post 2 survey (Day 35)
Cigarette quit attempts
A question: In the last 7 days, have you attempted to stop smoking cigarettes? (yes/no)
Time frame: Measured at baseline (Day 0) weekly surveys (Days 7, 14), post 1 survey (Day 21), and post 2 survey (Day 35)
E-cigarette quit attempts
A question: In the last 7 days, have you attempted to stop vaping? (yes/no)
Time frame: Measured at baseline (Day 0) weekly surveys (Days 7, 14), post 1 survey (Day 21), and post 2 survey (Day 35)
Forgoing cigarettes
A question: In the last 7 days, how many times did you stop yourself from having a cigarette because you wanted to smoke less? \[numerical response 0-250\]
Time frame: Measured at baseline (Day 0) weekly surveys (Days 7, 14), post 1 survey (Day 21), and post 2 survey (Day 35)
Forgoing e-cigarettes
A question: In the last 7 days, how many times did you stop yourself from vaping because you wanted to smoke less? \[numerical response 0-250\]
Time frame: Measured at baseline (Day 0) weekly surveys (Days 7, 14), post 1 survey (Day 21), and post 2 survey (Day 35)
Plan to share: Undecided — With the small sample size, we would want to ensure participants are not identifiable.
Ran from May 2026 to primary completion in Jul 2026, 1 month.
Of 184 non-industry interventional studies with no phase under Vaping, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's 1 month is below that.
Counting every sponsor, half of 208 studies reached it within 18 months; a quarter within 6 and three quarters within 31.
Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → May 2026, on Oct 28, 2026.
Primary completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Jul 2026, last on Oct 28, 2026.
Completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Jul 2026, last on Oct 28, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
UNC Lineberger Comprehensive Cancer Center →